CheckPoint Sciences has established a genomics laboratory and bioinformatic services collaboration with one of the world’s leading genetics and genomic labs, the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai (the “Icahn Institute at Mount Sinai”) (click here). The Icahn Institute at Mount Sinai in New York was founded in 2011 to help advance precision medicine with cutting-edge technologies and world-class computational and analytical resources. The collaboration is led by the CheckPoint Sciences’ Science Advisory Board, which includes several of the foremost cancer immunotherapy experts from The Tisch Cancer Institute and the Icahn Institute.
The collaboration provides our pharmaceutical and biotech clients with a comprehensive suite of capabilities and services necessary for the development, validation and commercialization of immunotherapy response-predictive companion diagnostics:
Access to Mount Sinai’s world class team of immunology, oncology, genomics and bioinformatics scientists and medical professionals.
Access to CheckPoint Sciences’ unique, patent-pending immunotherapy blood-based biomarkers. These response predictive biomarker capabilities address checkpoint inhibitors, combination therapies and personalized therapeutic cancer vaccines.
Access to The Icahn Institute at Mount Sinai’s state-of-the-art technical resources, including next generation platforms from Applied Biosystems, Illumina and Pacific Biosciences. Technology platforms (click here) available in particular to CheckPoint Sciences under this Collaboration include:
DNA Sequencing and Nucleic Acid Characterization Instruments
Supercomputer High-performance Computing Infrastructure
The collaboration team of CheckPoint Sciences and The Icahn Institute at Mount Sinai welcome the opportunity to meet with pharmaceutical and biotech companies to explore programs for the commercialization of response-predictive companion diagnostics for their immunotherapy drugs in the market and in their pipelines. For inquiries, please contact Karl G. Wassmann, President of CheckPoint Sciences, at email@example.com or (774) 893-4313.